Norvir (ritonavir)
- Region
- 🇪🇺 EU
- Active substance
- ritonavir
- Company
- AbbVie Deutschland GmbH & Co. KG
- Status
- Authorised
- Therapeutic area
- HIV Infections
- CHMP opinion
- Thu 23 May 1996
- EU approval
- Sun 25 Aug 1996
- Application
- EMEA/H/C/000127
- ATC
- J05AE03
- Official record
- www.ema.europa.eu
Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients (adults and children of two years of age and older).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Ritonavir Viatris (previously Ritonavir Mylan) Authorised · Viatris Limited
- 🇪🇺 Paxlovid Authorised · Pfizer Europe MA EEIG
- 🇪🇺 Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan) Authorised · Viatris Limited
- 🇪🇺 Kaletra Authorised · AbbVie Deutschland GmbH & Co. KG
- 🇪🇺 Viekirax Withdrawn · AbbVie Deutschland GmbH & Co. KG
Follow Norvir
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.